Vera Therapeutics, Inc. - Class A Common Stock (NQ: VERA)
This page provides news headlines related to Vera Therapeutics, Inc. (Nasdaq: VERA), along with stock information and market updates. The articles cover various financial news, including analyst ratings, IPOs, and biotech sector movements from May and June 2021. One key highlight is Vera Therapeutics' IPO pricing below its target range in May 2021.
T. Rowe Price (VERA) reports 4.57M shares, 6.4% ownership (Amendment)
T. Rowe Price Associates, Inc. has filed an Amendment No. 3 to Schedule 13G/A, disclosing beneficial ownership of 4,573,684 shares of Vera Therapeutics Inc. common stock, which represents 6.4% of the class. The filing specifies sole voting power over 4,570,810 shares and sole dispositive power over 4,573,684 shares. Notably, T. Rowe Price explicitly denies beneficial ownership in the filing, stating it should not be construed as an admission.
Vera Therapeutics, Inc. - Class A Common Stock (NQ: VERA)
This page provides a collection of recent news headlines related to Vera Therapeutics, Inc. (Nasdaq: VERA), primarily from Benzinga and The Motley Fool. The articles cover analyst forecasts, quarterly earnings recaps, stock movements, and updates on clinical trials and insider trading. The content highlights significant stock performance events and regulatory updates for the company.
Vera Therapeutics president and CEO sells $679,747 in stock
Fordyce Marshall, President and CEO of Vera Therapeutics, Inc. (NASDAQ:VERA), sold approximately $679,747 worth of Class A Common Stock on May 12, 2026, under a Rule 10b5-1 trading plan. The sales involved 18,500 shares across two transactions at weighted-average prices around $36.63 and $37.08. Despite a 23% year-to-date decline, VERA shares have seen an 81% return over the past year, while the company maintains a strong financial position with more cash than debt.
Vera Therapeutics president and CEO sells $679,747 in stock By Investing.com
Vera Therapeutics President and CEO, Fordyce Marshall, sold approximately $679,747 worth of Class A Common Stock on May 12, 2026, across two separate transactions. Despite an 81% return for VERA shares over the past year, the stock has declined 23% year-to-date and is considered undervalued by InvestingPro. Marshall still retains a significant number of shares, both directly and indirectly, and the company has recently received positive analyst upgrades and appointed a new board member.
Vera Therapeutics (VERA) CEO sells 18,500 shares under 10b5-1 plan
Vera Therapeutics (VERA) President and CEO Marshall Fordyce sold a total of 18,500 shares of Class A common stock on May 12, 2026. The sales were executed under a pre-established Rule 10b5-1 trading plan adopted on January 9, 2026, with the shares sold in two tranches at weighted-average prices of $37.0868 and $36.6396. Following these transactions, Fordyce's indirect holdings through a trust and a GRAT still exceed 200,000 shares.
A Look At Vera Therapeutics (VERA) Valuation After FDA Priority Review For Atacicept In IgA Nephropathy
Vera Therapeutics (VERA) is facing a critical period with its drug atacicept awaiting FDA review for IgA nephropathy, despite reporting a significant net loss in the first quarter. While the stock has seen recent declines, its long-term shareholder return remains strong, and analysts anticipate high revenue and earnings growth. The company's valuation appears high based on its P/B ratio compared to industry averages, but a Discounted Cash Flow model suggests a substantial undervaluation relative to future cash flow estimates.
Does Vera’s Widening Quarterly Net Loss Reframe the Bull Case for Vera Therapeutics (VERA)?
Vera Therapeutics (VERA) reported a significant increase in its Q1 2026 net loss, reaching US$121.03 million, more than double the previous year, primarily due to heavy upfront spending on atacicept development. This widening loss intensifies questions about cash burn, future financing, and potential equity dilution. Despite this, the investment narrative still centers on atacicept's IgA nephropathy opportunity and the upcoming FDA PDUFA date of July 7, 2026.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics, Inc. announced inducement awards for ten new employees, granted on May 4, 2026, under its 2024 Inducement Plan. These awards include non-qualified stock options to purchase 40,250 shares and restricted stock units (RSUs) underlying 20,125 shares, approved in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options and RSUs will vest over four years, contingent on continued employment.
Ten new hires get Vera stock awards tied to 60,375 shares
Vera Therapeutics (Nasdaq: VERA) announced inducement awards on May 4, 2026, granting non-qualified stock options for 40,250 shares and Restricted Stock Units (RSUs) for 20,125 shares to ten new employees under its 2024 Inducement Plan. The stock options have an exercise price of $35.51, matching the closing price on the grant date, and both options and RSUs will vest over four years, subject to continued employment. This move follows similar grants and aims to attract and retain talent in line with Nasdaq Listing Rule 5635(c)(4).
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics has announced inducement awards for ten new employees, consisting of non-qualified stock options to purchase 40,250 shares and restricted stock units (RSUs) underlying 20,125 shares of Class A common stock. These grants were made on May 4, 2026, under the company's 2024 Inducement Plan, with an exercise price of $35.51 per stock option. The awards are structured with vesting schedules over four years, contingent on continued employment.
B-K] Vera Therapeutics, Inc. Reports Material Event
Vera Therapeutics, Inc. reported its first-quarter 2026 financial results and provided business updates, highlighting the FDA's Priority Review for atacicept for IgA nephropathy with a PDUFA date of July 7, 2026. The company posted a net loss of $121.0 million, an increase from the previous year, as it ramped up R&D and commercial launch preparations. Vera Therapeutics confirmed it has sufficient cash reserves and debt facilities to fund operations through the potential approval and U.S. commercial launch of atacicept.
Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference
Vera Therapeutics, Inc. announced its management team will present at the Bank of America Securities 2026 Health Care Conference in Las Vegas from May 12-14, 2026. The company, focused on developing treatments for serious immunological diseases, will also hold one-on-one investor meetings. A webcast of the presentation on May 13, 2026, at 4:20 PM PDT will be available, with a replay accessible on their website.
Fordyce, Vera Therapeutics CEO, sells $1m in VERA stock By Investing.com
Marshall Fordyce, President and CEO of Vera Therapeutics, Inc. (NASDAQ:VERA), sold 22,951 shares of Class A Common Stock for over $1 million on April 14, 2026. These sales, executed under a pre-arranged trading plan, occurred as VERA stock saw significant gains, with the company currently valued at $3.1 billion and its next earnings report due on May 7. The article also notes recent positive analyst ratings and strategic appointments within Vera Therapeutics.
Fordyce, Vera Therapeutics CEO, sells $1m in VERA stock
Marshall Fordyce, President and CEO of Vera Therapeutics, Inc., sold 22,951 shares of Class A Common Stock for over $1 million on April 14, 2026, through a pre-arranged trading plan. This sale occurred while VERA stock has shown significant gains, and analyst ratings remain positive, with the company valued at $3.1 billion ahead of its next earnings report.
[Form 4] Vera Therapeutics, Inc. Insider Trading Activity
Vera Therapeutics, Inc.'s President and CEO, Marshall Fordyce, reported open-market sales of Class A Common Stock on April 14, 2026. These transactions, executed under a pre-arranged Rule 10b5-1(c) trading plan, involved the sale of 22,951 shares totaling approximately $1.01 million. Following these sales, Fordyce retains significant direct and indirect holdings in the company.
Fordyce, Vera Therapeutics CEO, sells $1m in VERA stock
Marshall Fordyce, President and CEO of Vera Therapeutics, Inc. (NASDAQ:VERA), sold 22,951 shares of Class A Common Stock worth over $1 million on April 14, 2026, under a pre-arranged 10b5-1 trading plan. Despite the insider sale, VERA stock has performed strongly, gaining 10% in the past week and 105% in the past year, and analysts have recently reiterated Buy and Overweight ratings with positive price targets. The company, valued at $3.1 billion, is preparing for its next earnings report on May 7 and has made strategic appointments to its board and commercial team.
Vera Therapeutics (VERA) Valuation Check After Recent Share Price Rebound
Vera Therapeutics (VERA) has seen a recent share price rebound, up 10% in the past day and week, though year-to-date it's down 7.36%. The stock trades at a Price-to-Book ratio of 5.3x, which is above the US biotech industry average but below its direct peers, suggesting it's about right. However, a discounted cash flow (DCF) model from Simply Wall St indicates the stock is heavily undervalued, trading at US$45.04 against a calculated intrinsic value of US$436.34 per share, creating conflicting valuation signals for investors.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics, Inc. announced inducement awards to 89 new employees, consisting of non-qualified stock options to purchase 258,200 shares and restricted stock units (RSUs) for 131,925 shares of Class A common stock. These grants were made under the company's 2024 Inducement Plan and approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options and RSU awards will vest over four years, subject to continued employment.
Vera Therapeutics issues stock awards to 89 new employees
Vera Therapeutics announced it granted inducement awards to 89 new employees on April 8, 2026, under its 2024 Inducement Plan. These awards include non-qualified stock options for 258,200 shares and restricted stock units (RSUs) for 131,925 shares. The stock options have an exercise price of $40.33 and both options and RSUs vest over four years, aligning with Vera Therapeutics' strategy of using equity for hiring and retention.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics announced it granted inducement awards to 89 new employees, consisting of non-qualified stock options to purchase 258,200 shares and restricted stock units (RSUs) for 131,925 shares of Class A common stock. These awards, approved by the Compensation Committee, are in accordance with Nasdaq Listing Rule 5635(c)(4) and are designed to attract new talent. Both the stock options and RSUs will vest over a four-year period, subject to continued employment.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics, Inc. announced that its Compensation Committee granted inducement awards on April 8, 2026, to 89 new employees. These awards consist of non-qualified stock options to purchase 258,200 shares and restricted stock units (RSUs) for 131,925 shares of Class A common stock, issued under the company's 2024 Inducement Plan. The grants aim to incentivize new hires, with vesting periods set over four years for both stock options and RSUs.
Board of Vera Therapeutics (VERA) seeks votes on directors, auditor and say-on-pay
Vera Therapeutics (VERA) has scheduled its 2026 Annual Meeting of Stockholders for May 21, 2026, to be held virtually. Stockholders will vote on electing three Class II directors, ratifying KPMG LLP as the independent auditor for 2026, and approving an advisory "say-on-pay" resolution for executive compensation. The board recommends voting in favor of all three proposals.
Is It Too Late To Consider Vera Therapeutics (VERA) After Its Recent Share Price Surge?
Vera Therapeutics (VERA) has seen a significant share price surge, up 102.8% over the past year, prompting questions about its current valuation. A Discounted Cash Flow (DCF) analysis suggests the stock is significantly undervalued, estimating an intrinsic value of $436.72 per share against a recent price of $40.45. While its Price-to-Book (P/B) ratio of 4.77x is higher than the industry average, the overall assessment suggests the stock could still offer value, especially considering future cash flow projections.
Vera Therapeutics Adds Experienced Legal Chief As Shares Trade Below Targets
Vera Therapeutics has appointed Jane Wright-Mitchell as its new Chief Legal Officer, bringing extensive legal and compliance experience to the company. This leadership change occurs as VERA shares trade below analyst targets and its estimated fair value, with mixed short-term returns but strong long-term growth. The appointment is significant for managing legal risks, partnerships, and intellectual property, especially for a clinical-stage biotech.
Point72 (NASDAQ: VERA) reports 1.7% holding, 1.23M shares disclosed
Point72-affiliated entities have reported a 1.7% beneficial stake in Vera Therapeutics (NASDAQ: VERA), totaling 1,229,525 shares as of March 31, 2026. This holding includes 17,800 shares exercisable from call options. The Schedule 13G filing indicates a passive investment intent, with shared voting and dispositive power among Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen.
Is Vera Therapeutics (VERA) Pricing Reflect Its DCF Upside After Recent Share Price Weakness
Vera Therapeutics (VERA) has experienced recent stock price weakness but shows significant long-term returns. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 88.5%, with an intrinsic value of about US$338.10 per share compared to its current price of US$38.86. However, its Price-to-Book ratio of 4.59x is above the biotech industry average, indicating it's about right by that metric.
VERA SEC Filings - Vera Therapeutics, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive overview of Vera Therapeutics (VERA) SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading reports. It highlights key events like clinical trial data, financing transactions, and governance changes, with AI-powered summaries to help investors quickly parse crucial information. The article also details recent Form 144 sales and insider equity awards for executives.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics announced inducement awards to Jane Wright-Mitchell, its new Chief Legal Officer, in accordance with Nasdaq Listing Rule 5635(c)(4). These awards include non-qualified stock options for 56,850 shares and restricted stock units (RSUs) for 42,403 shares of Class A common stock. The stock options have an exercise price of $40.73 and will vest over four years, while the RSU award will also vest over four years.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics announced inducement awards to Jane Wright-Mitchell, its new Chief Legal Officer, consisting of non-qualified stock options and restricted stock units. These awards were approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4) as a material inducement for her employment. The stock options and RSUs have specific vesting schedules over four years, contingent on her continued service.
New Vera legal chief gets 56,850 options and 42,403 RSUs
Vera Therapeutics (NASDAQ: VERA) has granted inducement equity awards to its new Chief Legal Officer, Jane Wright-Mitchell, consisting of 56,850 non-qualified stock options and 42,403 restricted stock units (RSUs). These awards, approved on March 23, 2026, are part of the company's 2024 Inducement Plan and vest over four years, aligning with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $40.73, matching Vera's closing price on the grant date.
Vanguard disaggregates holdings; Vera Therapeutics (VERA) shows 0 shares reported
Vanguard has amended its Schedule 13G/A for Vera Therapeutics (VERA) to report 0 shares beneficially owned, representing 0% of the class. This change is due to an internal realignment on January 12, 2026, where certain Vanguard subsidiaries will now report their beneficial ownership separately, relying on SEC Release No. 34-39538. This procedural amendment indicates a change in Vanguard's reporting structure rather than a complete divestment, as subsidiary holdings will be disclosed independently.
VERA SEC Filings - Vera Therapeutics, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive overview of Vera Therapeutics (VERA) SEC filings, including 10-K, 10-Q, and 8-K reports, as well as insider trading forms. It highlights key events such as sales agreements, public offerings, clinical trial updates (like the ORIGIN Phase 3 trial for atacicept), corporate governance changes, and financial reports. The platform, Stock Titan, offers AI-powered summaries to help investors quickly understand the content of these regulatory documents.
VERA SEC Filings - Vera Therapeutics, Inc. 10-K, 10-Q, 8-K Forms
This article provides a comprehensive overview of Vera Therapeutics, Inc.'s SEC filings, including 10-K, 10-Q, and 8-K forms, crucial for investors tracking the company's financial and operational developments. It details recent filings like equity awards for executives, ownership disclosures by institutional investors, and announcements regarding fundraising for the potential launch of its lead drug, atacicept. The platform offers AI-powered summaries to help users quickly understand key points from these regulatory documents.
VERA SEC Filings - Vera Therapeutics, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Vera Therapeutics, Inc. (VERA) SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading reports. It highlights the company's regulatory disclosures related to clinical milestones, financing, governance changes, and key events like at-the-market offerings and clinical trial data. The platform also offers AI-powered summaries and access to insider transaction details, crucial for investors tracking the biotechnology company's progress in immunological diseases.
Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer
Vera Therapeutics has appointed Jane Wright-Mitchell as its Chief Legal Officer, effective immediately. With over 25 years of experience in business and compliance law, Wright-Mitchell will leverage her expertise in regulatory approvals, commercialization, and intellectual property as the company prepares for the potential launch of its first-in-class dual BAFF/APRIL inhibitor for IgA nephropathy. Her experience previously as a strategic legal consultant for Vera Therapeutics and her background as General Counsel at Vaxcyte highlight her readiness for this significant role.
Equity grants to Vera Therapeutics (VERA) Chief Legal Officer detailed in Form 4
Vera Therapeutics' Chief Legal Officer, Jane Wright-Mitchell, received new equity awards comprising a stock option for 56,850 shares at an exercise price of $40.73 and 42,403 restricted stock units (RSUs). These grants are part of the company's compensation plan, with multi-year vesting schedules designed for retention and alignment with long-term company performance, rather than reflecting immediate stock market expectations. The awards are not open-market purchases or sales and were granted under the 2024 Inducement Plan.
Assessing Vera Therapeutics (VERA) Valuation As Price To Book And DCF Send Mixed Signals
Vera Therapeutics (VERA) is facing mixed valuation signals, with a Price-to-Book ratio of 4.7x suggesting it is overvalued compared to its peers and the biotech industry average, mainly due to its clinical stage and lack of revenue. However, a Discounted Cash Flow (DCF) model indicates the stock is trading at a significant discount (88.1%). Investors are urged to consider these conflicting signals and assess the inherent risks, including trial outcomes and ongoing losses, before making investment decisions.
Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer
Vera Therapeutics has appointed Jane Wright-Mitchell as Chief Legal Officer, bringing over 25 years of legal experience in the life sciences sector. Her expertise will be crucial as the company progresses towards the potential launch of its dual BAFF/APRIL inhibitor, atacicept, for IgA nephropathy. The company aims to advance treatments for serious immunological diseases and holds global developmental and commercial rights to its key product candidates.
Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer
Vera Therapeutics has appointed Jane Wright-Mitchell as its new Chief Legal Officer. Ms. Wright-Mitchell, who previously served as a strategic legal consultant for the company, brings over 25 years of experience in business and compliance law within the life sciences industry. Her expertise will be crucial as Vera Therapeutics advances towards the potential launch of its first-in-class dual BAFF/APRIL inhibitor for IgA nephropathy.
Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer
Vera Therapeutics, Inc. (Nasdaq: VERA) announced the immediate appointment of Jane Wright-Mitchell, Pharm.D., J.D., as its new Chief Legal Officer. Ms. Wright-Mitchell brings over 25 years of legal experience in the life sciences industry and will play a crucial role as Vera Therapeutics approaches the potential commercial launch of atacicept, its lead product candidate for IgA nephropathy. Her expertise in regulatory approvals, commercialization, and intellectual property management is expected to strengthen the company’s foundation for future success.
Investment Firm Boosts Vera Therapeutics Holding to $41.75M in 2026 - News and Statistics
Integral Health Asset Management expanded its stake in Vera Therapeutics by acquiring 100,000 shares valued at $3.55 million in February 2026, increasing its total holding to $41.75 million. This move comes as Vera Therapeutics, a clinical-stage biotech company, awaits a key FDA regulatory decision in July for its lead drug candidate, which has reported positive Phase 3 trial results. The company, which specializes in therapies for immunological diseases, finished the previous year with significant cash reserves, positioning it for commercialization efforts.
Vera Therapeutics (VERA) finance chief exercises options for 10,000 shares
Joseph R. Young, Vera Therapeutics' SVP of finance and chief accounting officer, exercised stock options to acquire 10,000 shares of Class A common stock at $3.9396 per share on March 13, 2026. Following this transaction, he directly owns 75,754 shares and holds 38,589 stock options. The filing indicates that 1,032 of his shares were obtained through the company's 2021 Employee Stock Purchase Plan, and the stock options vest over time.
Assessing Vera Therapeutics (VERA) Valuation As Deerfield Ups Stake And FDA Priority Review Nears
Deerfield Management Company has increased its stake in Vera Therapeutics (VERA) as the FDA priority review for its lead drug candidate, atacicept, approaches. Despite Vera's current losses, Simply Wall St's discounted cash flow (DCF) model suggests a significant undervaluation at $337.43 per share compared to its current price of $39.96, driven by strong growth forecasts. However, the company's price-to-book ratio is higher than peers, indicating a mixed valuation picture that warrants further investigation by investors.
Deep Track files 13G disclosing 5.50% stake in Vera Therapeutics (NASDAQ: VERA)
Deep Track Capital, LP and Deep Track Biotechnology Master Fund, Ltd. have filed a Schedule 13G, disclosing a beneficial ownership of 3,921,362 shares in Vera Therapeutics (NASDAQ: VERA). This represents a 5.50% stake in the company's Class A common stock, based on 71,355,667 shares outstanding as of February 23, 2026. David Kroin is identified as a control person for the Deep Track entities, holding shared voting and dispositive power over these shares.
Christopher Hite joins Vera Therapeutics (NASDAQ: VERA) board of directors
Vera Therapeutics (NASDAQ: VERA) announced the appointment of Christopher Hite to its board of directors as a Class III director, effective March 5, 2026. His initial term extends to the 2027 annual stockholders’ meeting, and his compensation aligns with the company's non-employee director policy. Hite received a stock option for 24,937 shares at an exercise price of $38.85, vesting monthly over three years, and will receive an annual cash retainer of $45,000, pro-rated for 2026.
Vera Therapeutics appoints Christopher Hite to Board as Class III Director
Vera Therapeutics (VERA) has appointed Christopher Hite to its Board of Directors as a Class III Director, effective March 5, 2026. Hite will be eligible for a nonstatutory option to purchase 24,937 shares and will receive an annual cash retainer of $45,000, pro-rated for 2026. This information is based on an SEC 8-K filing from March 9, 2026.
Vera Therapeutics Adds Christopher Hite to Board
Vera Therapeutics (VERA) has appointed Christopher Hite as a Class III director to its board, with his term ending in 2027. Hite received stock options and cash compensation, with future equity awards planned under standard independent board practices. Despite accelerating losses and cash burn, Spark’s AI Analyst rates VERA as Neutral due to a strong balance sheet and a recent equity raise cushioning financial flexibility.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics, Inc. announced inducement awards granted to six new employees under its 2024 Inducement Plan. These awards, approved by the Compensation Committee, consist of non-qualified stock options to purchase 46,000 shares and restricted stock units underlying 25,875 shares of Class A common stock. The grants are in accordance with Nasdaq Listing Rule 5635(c)(4) and are designed to incentivize new employees, with vesting periods set over four years.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics announced inducement grants on March 3, 2026, consisting of non-qualified stock options for 46,000 shares and restricted stock units for 25,875 shares, issued to six new employees. These awards, approved by the Compensation Committee, are designed as a material inducement for employment under Nasdaq Listing Rule 5635(c)(4) and are subject to vesting schedules over four years. The stock options have an exercise price matching the closing trading price on the grant date, and the RSUs' vesting commencement dates vary based on the employee's start date.
